Hexagon Capital Partners LLC Purchases 305 Shares of Pfizer Inc. (NYSE:PFE)

Hexagon Capital Partners LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 20,688 shares of the biopharmaceutical company’s stock after acquiring an additional 305 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Pfizer were worth $810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its holdings in shares of Pfizer by 36.5% during the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 267 shares during the period. Alpha DNA Investment Management LLC increased its stake in shares of Pfizer by 52.2% in the 1st quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 374 shares in the last quarter. Lake Point Wealth Management purchased a new stake in shares of Pfizer in the 2nd quarter worth $49,000. Harvest Fund Management Co. Ltd increased its stake in shares of Pfizer by 25,460.0% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,273 shares in the last quarter. Finally, Abundance Wealth Counselors purchased a new stake in shares of Pfizer in the 1st quarter worth $51,000. 64.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pfizer stock traded down $0.31 during trading on Friday, reaching $44.16. 561,335 shares of the stock traded hands, compared to its average volume of 30,776,777. The company has a market capitalization of $247.59 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 1.58 and a beta of 0.74. The business has a fifty day simple moving average of $44.95 and a two-hundred day simple moving average of $40.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12. Pfizer Inc. has a 52-week low of $33.36 and a 52-week high of $51.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.10. The firm had revenue of $18.98 billion during the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter last year, the business posted $0.78 earnings per share. On average, research analysts predict that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Friday, July 30th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date was Thursday, July 29th. Pfizer’s payout ratio is 70.27%.

Several equities research analysts have recently commented on PFE shares. JPMorgan Chase & Co. upped their price objective on Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a research note on Monday. SVB Leerink restated a “hold” rating and issued a $49.00 price objective on shares of Pfizer in a research note on Tuesday. Royal Bank of Canada set a $44.00 price objective on Pfizer in a research note on Thursday, July 29th. Berenberg Bank reiterated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, June 15th. Finally, Morgan Stanley increased their price target on Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 29th. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $42.77.

In related news, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the completion of the transaction, the senior vice president now owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 1,661 shares of the stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: What are earnings reports?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.